Skip to content
CA.gov logo in white
  • Grants Management System
  • CIRM Hub Portal
  • Contact
  • About
    • Our Mission
    • Our Impact
    • Our Governing Board
    • Strategic Goals
    • Our Team
    • Annual Reports
  • For Researchers
    • Funding Opportunities
    • Information for Applicants
    • Researcher Resources
    • Our Review Process
  • Our Programs
    • Grants Dashboard
    • Research and Development
    • Education and Training
    • Patient Access
  • Patient Resources
    • Stem Cell and Genetic Research
    • From Bench to Bedside
    • Community Outreach
    • Clinical Trials
    • Community Stories
  • News and Events
    • Press Releases
    • Public Meetings
    • Blog
    • Webinars and Workshops
  • About
    • Our Mission
    • Our Impact
    • Our Governing Board
    • Strategic Goals
    • Our Team
    • Annual Reports
  • For Researchers
    • Funding Opportunities
    • Information for Applicants
    • Researcher Resources
    • Our Review Process
  • Our Programs
    • Grants Dashboard
    • Research and Development
    • Education and Training
    • Patient Access
  • Patient Resources
    • Stem Cell and Genetic Research
    • From Bench to Bedside
    • Community Outreach
    • Clinical Trials
    • Community Stories
  • News and Events
    • Press Releases
    • Public Meetings
    • Blog
    • Webinars and Workshops

Treatment of Moderate to Severe Refractory Crohn’s Disease

  • Post author:
  • Post published:May 6, 2026
  • Post category:

Continue ReadingTreatment of Moderate to Severe Refractory Crohn’s Disease

Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

  • Post author:
  • Post published:April 20, 2026
  • Post category:

Continue ReadingStudy to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia

  • Post author:
  • Post published:April 20, 2026
  • Post category:

Continue ReadingOpen-Label Study of mRNA-3927 in Participants With Propionic Acidemia

A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH – SLE/LN)

  • Post author:
  • Post published:April 20, 2026
  • Post category:

Continue ReadingA Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH – SLE/LN)

A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants With Hearing Loss Due to Otoferlin Mutations

  • Post author:
  • Post published:April 20, 2026
  • Post category:

Continue ReadingA Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants With Hearing Loss Due to Otoferlin Mutations

Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency

  • Post author:
  • Post published:April 20, 2026
  • Post category:

Continue ReadingClinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency

Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury

  • Post author:
  • Post published:April 20, 2026
  • Post category:

Continue ReadingIltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury

A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma

  • Post author:
  • Post published:April 20, 2026
  • Post category:

Continue ReadingA Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma

An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency

  • Post author:
  • Post published:April 20, 2026
  • Post category:

Continue ReadingAn Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency

TLI, TBI, ATG & Hematopoietic Stem Cell Transplantation and Recipient T Regs Therapy in Living Donor Kidney Transplantation

  • Post author:
  • Post published:April 20, 2026
  • Post category:

Continue ReadingTLI, TBI, ATG & Hematopoietic Stem Cell Transplantation and Recipient T Regs Therapy in Living Donor Kidney Transplantation
  • 1
  • 2
  • 3
  • 4
  • 5
  • Go to the next page
  • Careers
  • Administrative & Financials
  • Accessibility

Subscribe to Receive CIRM News

Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox. 

Sign Up
Facebook-f X-twitter Instagram Linkedin Youtube
  • Privacy Policy
  • ©2025 California Institute for Regenerative Medicine
  • Media Guidelines
  • Contact Us